A six-month produce prescription program in Los Angeles clinics shows how food-as-medicine strategies can meaningfully improve access to healthy foods for patients with diabetes, but reveals why affordability remains a…
Specialty Please choose I’m not a medical professional. Allergy and Immunology Anatomy Anesthesiology Biostatistics Cardiac/Thoracic/Vascular Surgery Cardiology Critical Care Dentistry Dermatology Diabetes and Endocrinology Emergency Medicine Epidemiology and Public Health…
Higher Uric Acid at Diagnosis Linked to Complications in Young T1DM Patients: Study We use cookies for analytics, advertising and to improve our site. You agree to our use of…
Diabetes patients can enjoy festival sweets like Ariselu by following the “Vegetables First” rule to control blood sugar spikes.
Specialty Please choose I’m not a medical professional. Allergy and Immunology Anatomy Anesthesiology Biostatistics Cardiac/Thoracic/Vascular Surgery Cardiology Critical Care Dentistry Dermatology Diabetes and Endocrinology Emergency Medicine Epidemiology and Public Health…
Specialty Please choose I’m not a medical professional. Allergy and Immunology Anatomy Anesthesiology Biostatistics Cardiac/Thoracic/Vascular Surgery Cardiology Critical Care Dentistry Dermatology Diabetes and Endocrinology Emergency Medicine Epidemiology and Public Health…
Results from a population-based study published by investigators in Drug Safety demonstrate that dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) could reduce the risk…
Specialty Please choose I’m not a medical professional. Allergy and Immunology Anatomy Anesthesiology Biostatistics Cardiac/Thoracic/Vascular Surgery Cardiology Critical Care Dentistry Dermatology Diabetes and Endocrinology Emergency Medicine Epidemiology and Public Health…
Credit: CC0 Public Domain For those with type 2 diabetes who have knee osteoarthritis, getting a knee replacement can be difficult because they are more likely to have surgical complications.…
PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutics being developed…